Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (November 2021)
19 slides from Resonance Health's investor presentation, Nov 25, 2021
Slide 1: Investor Presentation November 2021
INVESTOR PRESENTATION NOVEMBER 2021
Slide 2: Positioning for Growth
2 ANNUAL REPORT TEMPLATE MINIMAL DESIGN 2016/2107 Positioning for Growth (ASX: RHT)
Slide 3: Disclaimer
INVESTOR PRESENTATION NOVEMBER 2021 3 DISCLAIMER This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to a number of factors and uncertainties that c
Slide 4: Resonance Health company overview
4 NOVEMBER ANNUAL REPORT 2021 TEMPLATE INVESTOR PRESENTATION MINIMAL DESIGN 2016/2107 Resonance Health is a global leader in the diagnosis and measurement of iron or fat in human organs, including the liver, heart, spleen, and brain. ASX: RHT Mission To develop innovative healthcare products and ser
Slide 5: Presentation Outline and Share Price
INVESTOR PRESENTATION NOVEMBER 2021 5 PRESENTATION OUTLINE 1. New Global Salesforce ASX RHT(* at 24/11/21) Share price 0.12* 2. Introducing LiverSmart™ Shares on issue 461.1m Market Capitalisation $55.33m* 3. Prolific (and growing) Diseases Cash at Bank $8.4m (30/9) Enterprise Value $63.73m* 4. High
Slide 6: 1. New Global Salesforce
6 NOVEMBER 2021 INVESTOR PRESENTATION 1. NEW GLOBAL SALESFORCE REVENUE BY PRODUCT (FY 20/21) REVENUE BY REGION (FY 20/21) Key Salesforce Initiatives • Activating KOLs • Clinical Trials (High Priority) • Conference Participation • Disciplined CRM Approach FerriScan Cardiac T2* USA Great Britain Canad
Slide 7: New Markets Targeted
MINIMALINVESTOR PRESENTATION DESIGN 2016/2107 NOVEMBER ANNUAL REPORT 2021 TEMPLATE 7 NEW MARKETS TARGETED New AI devices enable new market penetration Sales Personnel 80% of patients with liver iron Australia 2 disorders are in Germany 1 new untapped India 2 markets South Korea 1 UK 2 USA 3 New Mark
Slide 8: 2. Introducing LiverSmart
8 8 NOVEMBER ANNUAL REPORT 2021 TEMPLATE MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 2. INTRODUCING LIVERSMART ™ Applying to FDA for US Regulatory Clearance AI automatically analyses MRI images and reports: • Liver Iron Concentration (LIC) • Proton Density Fat Fraction (PDFF) • Volumetric Liver Fa
Slide 9: Combining the Best in Fat and Iron
MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 ANNUAL REPORT NOVEMBER 2021 TEMPLATE 9 9 COMBINING THE BEST IN FAT AND IRON “LiverSmart is an evolution of our existing product offering and responds to the growing trend in medical imaging for a more holistic assessment of human organs. We have used art
Slide 10: 3. Prolific (and Growing) Diseases
1010 ANNUAL 2021 NOVEMBER REPORT TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 3. PROLIFIC (AND GROWING) DISEASES Deployed Products Product Product description Main Diseases Disease Prevalence* • Measures liver iron concentration (LIC) • Thalassaemia • 330K births annually • Manual analysi
Slide 11: 3. Prolific (and Growing) Diseases: R&D Initiatives
MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 ANNUAL REPORT NOVEMBER TEMPLATE 2021 1111 3. PROLIFIC (AND GROWING) DISEASES R&D Initiatives Product Product description Main Diseases Disease Prevalence* • Measures liver iron concentration and liver fat • Thalassaemia • 330K births annually • Automate
Slide 12: 4. High Impact Innovation & R&D - Near Term
1212 ANNUAL REPORT NOVEMBER 2021 TEMPLATE MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 4. HIGH IMPACT INNOVATION & R&D - NEAR TERM Proof of Concept Study Preparation Data Collection Validation Regulatory Clearance Implementation Shorter Acqusition - FerriScan 3T Scanner Calibration - FerriScan Shor
Slide 13: 4. High Impact Innovation & R&D - Medium Term
INVESTOR MINIMAL PRESENTATION DESIGN 2016/2107 ANNUAL REPORT NOVEMBER 2021 TEMPLATE 13 4. HIGH IMPACT INNOVATION & R&D - MEDIUM TERM Proof of Concept Study Preparation Data Collection Validation Regulatory Clearance Implementation Alert-PE LungSmart (CF) Cardiac T2* AI FAST Upgrade ALERT-PE: • AI re
Slide 14: 4. High Impact Innovation & R&D - Longer Term
14 NOVEMBER 2021 INVESTOR PRESENTATION 4. HIGH IMPACT INNOVATION & R&D - LONGER TERM Discovery In vitro Validation Preclinical Validation Pharmacology and Toxicology Implementation ASON Project - Chronic Hepatitis B ASON Project - Hepatitis D ASON Project - HIV ASON Project - Hepatitis C Secondary A
Slide 15: Well Balanced Portfolio
INVESTOR PRESENTATION NOVEMBER 2021 15 WELL BALANCED PORTFOLIO MARKET DEVELOPMENT DIVERSIFICATION New Markets LIVERSMART ALERT-PE FERRISMART ASON PROJECT HEPAFAT-AI BLOOD MARKERS LUNGSMART (CF) MARKET PENETRATION PRODUCT DEVELOPMENT Existing Markets FERRISCAN SHORTER ACQUISITION HEPAFAT-SCAN 3T CALI
Slide 16: 20/21 FY Results
16 ANNUAL NOVEMBER REPORT 2021 TEMPLATE MINIMAL INVESTOR PRESENTATION DESIGN 2016/2107 20/21 FY RESULTS (CASH AT 30/6) $8.86M $3.78M $0.6M* CASH REVENUE NPAT BALANCE • Revenue for the FY 20/21 was $3.78m, an increase of 3% versus the previous year • Cash on hand at 30 June 2021 of $8.86m, versus $6.
Slide 17: Experienced and Qualified Team
MINIMAL INVESTORDESIGN PRESENTATION 2016/2107 ANNUAL REPORT NOVEMBER 2021 TEMPLATE 17 EXPERIENCED AND QUALIFIED TEAM Board • Dr Martin Blake Non-executive Chairman • Mr Simon Panton Non-executive Director • Dr Travis Baroni Non-executive Director • Mr Mitchell Wells Managing Director Executive • Mit
Slide 18: Investors Overview
INVESTOR PRESENTATION NOVEMBER 2021 18 INVESTORS OVERVIEW LARGEST SHAREHOLDERS (AS OF 24 NOVEMBER 2021) Rank Name Units % of Units 1 SOUTHAM INVESTMENTS 2003 PTY LTD 73,300,000 15.89 2 HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 44,285,296 9.60 3 ACUITY CAPITAL INVESTMENT MANAGEMENT PTY LTD 20,000,000
Slide 19: Investor Presentation
INVESTOR PRESENTATION Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and analysis services. 141 Burswood Road, Burswood WA 6100 Telephone: +61 (0)8 9286 5300 Fax: +61 8 9286 5399 E-mail: info@reson
Resonance Health — Investor Presentation (November 2021) on 6ix